Overview
DEBRA organizations, including DEBRA of America and DEBRA Research, support pharmaceutical R&D for Epidermolysis Bullosa (EB) therapies through research funding, infrastructure projects like patient registries and biobanks, and partnerships with industry. They facilitate clinical trial networks, preclinical models, and collaborations with pharma companies such as LEO Pharma to advance EB treatments. These non-profits connect developers with patient communities and global experts to accelerate therapy development.
Frequently asked questions
- What research infrastructure does DEBRA provide for EB drug development?
- DEBRA Research builds patient registries, biobanks, disease models, and clinical trial networks to support preclinical and clinical phases of EB therapy development.
- Does DEBRA partner with pharmaceutical companies for EB treatments?
- Yes, DEBRA Research collaborates with pharma like LEO Pharma on strategic partnerships to advance EB research and clinical applications.
- What are DEBRA's geographic capabilities for EB research support?
- DEBRA operates worldwide through DEBRA International's network of nearly 50 national groups, with DEBRA Research focusing on global collaborations across academia, industry, and regulators.